Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-LM3
- Development stage
- Unknown
- Lead developer
- University Hospital Basel
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-NODAGA-LM3 is a radiopharmaceutical diagnostic agent used for positron emission tomography (PET) imaging of neuroendocrine tumors (NETs). It consists of the somatostatin receptor (SSTR) antagonist peptide LM3 (p-Cl-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2) conjugated to the chelator NODAGA and labeled with the positron-emitting radioisotope Gallium-68. Unlike conventional SSTR agonists such as 68Ga-DOTATATE, LM3 acts as an antagonist, binding to SSTR2 on the tumor cell surface without triggering receptor internalization. This mechanism allows for high tumor-to-background ratios and potentially higher sensitivity in detecting SSTR-positive lesions, as antagonists can bind to a broader range of receptor states. It is primarily being developed for the localization and staging of well-differentiated neuroendocrine tumors and serves as the diagnostic companion to the therapeutic agent 177Lu-labeled LM3.
- Other names
- 68Ga-LM3Gallium-68 NODAGA-LM3Gallium68 NODAGA-LM3Gallium 68 NODAGA-LM3
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 68Ga-NODAGA-LM3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NODAGA-LM3.